Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics
Harrison, Simon J., Perrot, Aurore, Alegre, Adrian, Simpson, David, Wang, Ming Chung, Spencer, Andrew, Delimpasi, Sosana, Hulin, Cyrille, Sunami, Kazutaka, Facon, Thierry, Vlummens, Philip, Yong, Kwee, Campana, Frank, Inchauspé, Marlène, Macé, Sandrine, Risse, Marie‐Laure, Velde, Helgi, Richardson, Paul
Published in British journal of haematology (01.07.2021)
Published in British journal of haematology (01.07.2021)
Get full text
Journal Article
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
Martin, Tom, Richardson, Paul G, Facon, Thierry, Moreau, Philippe, Perrot, Aurore, Spicka, Ivan, Bisht, Kamlesh, Inchauspé, Marlene, Casca, France, Macé, Sandrine, Van de Velde, Helgi, Suzuki, Kenshi
Published in Haematologica (Roma) (01.10.2022)
Published in Haematologica (Roma) (01.10.2022)
Get full text
Journal Article
Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis
Harrison, Simon J., Richardson, Paul G., Alegre, Adrian, Simpson, David, Wang, Ming Chung, Spencer, Andrew, Delimpasi, Sossana, Hulin, Cyrille, Sunami, Kazutaka, Facon, Thierry, Vlummens, Philip, Yong, Kwee, Campana, Frank, Inchauspé, Marlène, Macé, Sandrine, Risse, Marie-Laure, van de Velde, Helgi, Attal, Michel
Published in Clinical lymphoma, myeloma and leukemia (01.10.2019)
Published in Clinical lymphoma, myeloma and leukemia (01.10.2019)
Get full text
Journal Article
Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results
Quach, Hang, Parmar, Gurdeep, Ocio, Enrique, Prince, H. Miles, Oriol Rocafiguera, Albert, Tsukada, Nobuhiro, Sunami, Kazutaka, Bories, Pierre, Karanes, Chatchada, Madan, Sumit, Semiond, Dorothee, Inchauspe, Marlene, Macé, Sandrine, Musholt, Petra B., Suzan, Florence, Moreau, Philippe
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
MM-071 Subcutaneous (SC) Isatuximab (Isa) Administration by an On-Body Delivery System (OBDS) in Combination With Pomalidomide-Dexamethasone (Pd) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients: Interim Phase 1b Study Results
Quach, Hang, Parmar, Gurdeep, Ocio, Enrique M., Prince, H. Miles, Oriol, Albert, Tsukada, Nobuhiro, Sunami, Kazutaka, Bories, Pierre, Karanes, Chatchada, Madan, Sumit, Semiond, Dorothee, Inchauspe, Marlene, Macé, Sandrine, Suzan, Florence, Moreau, Philippe
Published in Clinical lymphoma, myeloma and leukemia (01.10.2022)
Published in Clinical lymphoma, myeloma and leukemia (01.10.2022)
Get full text
Journal Article
Poster: MM-071 Subcutaneous (SC) Isatuximab (Isa) Administration by an On-Body Delivery System (OBDS) in Combination With Pomalidomide-Dexamethasone (Pd) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients: Interim Phase 1b Study Results
Quach, Hang, Parmar, Gurdeep, Ocio, Enrique M., Prince, H. Miles, Oriol, Albert, Tsukada, Nobuhiro, Sunami, Kazutaka, Bories, Pierre, Karanes, Chatchada, Madan, Sumit, Semiond, Dorothee, Inchauspe, Marlene, Macé, Sandrine, Suzan, Florence, Moreau, Philippe
Published in Clinical lymphoma, myeloma and leukemia (01.10.2022)
Published in Clinical lymphoma, myeloma and leukemia (01.10.2022)
Get full text
Journal Article
P-267: Subcutaneous isatuximab administration by an on-body delivery system in combination with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: interim phase 1b study results
Quach, Hang, Parmar, Gurdeep, Ocio, Enrique, Prince, H Miles, Oriol, Albert, Tsukada, Nobuhiro, Sunami, Kazutaka, Bories, Pierre, Karanes, Chatchada, Madan, Sumit, Semiond, Dorothee, Inchauspe, Marlene, Macé, Sandrine, Suzan, Florence, Moreau, Philippe
Published in Clinical lymphoma, myeloma and leukemia (01.08.2022)
Published in Clinical lymphoma, myeloma and leukemia (01.08.2022)
Get full text
Journal Article